Agios Pharmaceuticals Shares Drop Following FDA Review Extension for Pyrukynd
Agios Pharmaceuticals (AGIO) saw its stock price decline by over 12% on Friday following news that the U.S. Food and Drug Administration (FDA) has extended its review period for a marketing application. The extension pertains to a proposed label expansion for Pyrukynd, the company's lead product. The FDA had previously granted priority review for this application in July. This three-month delay in the regulatory decision-making process has introduced uncertainty regarding the timeline for potential commercial growth through the expanded indication.
Tickers: $AGIO
Topics: FDA extension label expansion stock price drop
Read the full article at Seeking Alpha
Part of the story Agios Pharmaceuticals Shares Drop Following FDA Review Extension for Pyrukynd (2 articles)